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The debate on the appropriate treatment of patients with papillary thyroid cancer (PTC) has persisted for several decades. The
main controversies focus on the extent of surgery, the timing of central neck dissection, and the indications for radioactive iodine
ablation. These controversies continue, for the most part, due to the good prognosis of PTC patients and the questionable eﬀect
thesetreatmentmodalitieshaveonpatientsurvival.Thispaperaddressesthesethreecontroversiesandtheroleofmoleculartumor
markers in the appropriate treatment selection.
1.Introduction
Papillary thyroid cancer (PTC) is both the most common
thyroid malignancy and is also the least aggressive thy-
roid cancer. For this reason, debate has centered on the
appropriate extent of treatment, including the extent of
surgery (lobectomy versus total thyroidectomy), timing of
central neck dissection (prophylactic versus therapeutic),
and indications for radioactive iodine ablation and TSH
suppressive therapy. There has been a shift in treatment
paradigm, as outlined by the most recent American Thy-
roid Association (ATA) management guidelines, to a risk-
stratiﬁed, selective management approach [1]. The risk-
stratiﬁcation is based on the risk of recurrence: (1) low
risk-completely resected, well-encapsulated tumor, without
extrathyroidal extension, without local or distant metastases,
absence of aggressive histology, and absence of vascular
invasion, (2) intermediate risk-microscopic extrathyroidal
invasion,cervicallymphnodemetastases, 131Iuptak eoutside
the thyroid bed, and aggressive histology (tall cell, insular,
columnar cell carcinoma), or vascular invasion, and (3)
high-risk macroscopic tumor invasion, incomplete tumor
resection, and distant metastases [1]. These guidelines serve
as a guide for the appropriate management of thyroid
cancer patients. Yet, despite the plethora of studies on PTC
controversy still exists regarding the appropriate extent of
treatment. This paper focuses on the three most debated
areas in the management of PTC and addresses the utility of
molecular markers in operative decision making.
2. Extentof Surgery
The extent of disease aﬀects outcomes for PTC. It is
uniformly established that patients with PTC and high-risk
features and lymph node metastases have an increased risk of
recurrenceandmortalityandsubstantiatestotalornear-total
thyroidectomy when it can be done safely [2]. This approach
also beneﬁts patients with bilateral tumors, tumors with
obvious local invasion, and tumors with distant metastases
[3, 4]. Furthermore, total thyroidectomy reduced the risk
of persistent or recurrent disease, facilitated postoperative
131I ablation and whole body scanning, and allows for more
sensitive postoperative thyroglobulin monitoring. On the
other hand, a minority of experts argue that nearly 80% of
patients with PTC can be cured with a thyroid lobectomy
and isthmusectomy [5]. Lobectomy eliminates the need
for lifelong thyroid hormone replacement and reduces the
risk of complications (permanent hypoparathyroidism and
recurrent laryngeal nerve injury) [6].2 ISRN Oncology
Conﬂicting data exists in the literature on the optimal
surgical approach given that there are no prospective,
randomized studies addressing the issue. Retrospective data
suggest that local recurrence and disease-speciﬁc mortality
are reduced with a total thyroidectomy compared to subtotal
resections [2, 7, 8]. It has been reported that up to 10% of
patients treated with lobectomy alone have recurrence in the
contralateral lobe and that near-total and total thyroidec-
tomy decrease the risk of recurrent disease [9]. There is also
a risk of leaving residual cancer in the contralateral lobe,
since more than 50% of patients with PTC have bilateral
multifocal disease. Furthermore, even low-risk patients with
PTC treated with a lobectomy have a 19% risk of developing
nodal metastases at 20 years, compared to 6% for those
treated with total or near-total thyroidectomy [9]. Other
studies, however, have shown that recurrence and survival
is not aﬀected by the extent of surgery in low-risk patients
[5, 10] or even in high-risk patients [11].
Thediﬀerencesinoutcomedatareﬂectstheselectionbias
inherit in retrospective studies. The limitation of selection
bias is exempliﬁed in a recent study that concluded that a
lobectomy and total thyroidectomy resulted in equivalent
survival [12]. However, the perplexing aspect of the study
was the ﬁnding that the near-total thyroidectomy group had
an inferior survival compared to the total thyroidectomy
group [12]. The authors’ attribute this diﬀerence to good
patient selection in the use of lobectomy. As a result, the
authors’ support a lobectomy in patients with low-risk fea-
tures. Low-risk patients were deﬁned as those with unilateral
tumors, tumors < 4cm, and no evidence of extrathyroidal
extension, cervical lymphadenopathy, or distant metastases
[12]. However, others have shown that lobectomy alone was
associated with a 2.5-fold risk or recurrence and 2.2-fold risk
of death compared to those who underwent near-total or
total thyroidectomy [13].
Although size is utilized as one criterion for lobectomy,
a comprehensive population-based study of over 52,000
patients demonstrated that tumor size aﬀects outcome in
patients with PTC [2]. Size was found to directly aﬀect
recurrence;the10-yearrecurrenceratewas4.6%intumors<
1 cm, 7.1% in 1.0–1.9 cm, 8.6% in 2.0–2.9cm, 11.6% in 3.0–
3.9cm, 17.2% in 4.0–7.9cm, and 24.8% in tumors > 8.0cm
[2]. The extent of thyroidectomy also aﬀected the recurrence
rate and overall survival. The 10-year recurrence was 7.7%
for patients treated with total thyroidectomy compared to
9.8% for those who underwent lobectomy (P<0.05). In
addition, the authors’ reported that patients with PTC ≥
1.0cm who were treated with a lobectomy had a 15% higher
risk of recurrence and a 31% higher risk of death compared
to those treated with total thyroidectomy. In subset analysis,
this statistical diﬀerence was also apparent for tumors 1.0 to
2.0cm (24% higher risk of recurrence and 49% higher risk
of death) [2]. However, there was no diﬀerence in recurrence
rates and survival for patients with tumors < 1cmtreated
with either lobectomy or total thyroidectomy. This study
concluded that due to the improved clinical outcomes a
total thyroidectomy should be performed for PTC ≥ 1.0cm.
Based upon this study and others, the American Thyroid
Association guidelines committee recommended near-total
ortotalthyroidectomyforpatientswithPTClargerthan1cm
[1].
A recent study, utilizing the Surveillance, Epidemiology,
and End Results program database of the National Cancer
Institute, questions the validity of the most recent ATA
guidelines [14]. The most pressing criticism these authors’
had of the study conducted by Bilimoria et al. [2]w a s
the omitted data on disease-speciﬁc survival. In this study,
nearly 23,000 patients with PTC were analyzed with a mean
follow-up of 9.1 years. Mendelsohn et al. [14]c o n ﬁ r m e d
ﬁndings from prior reports that demonstrate lower disease-
speciﬁc survival with increasing tumor size, extrathyroidal
extension, advanced age, and positive lymph node status.
Interestingly, this study showed that on multivariate analysis,
there was no diﬀerence in overall- or disease-speciﬁc survival
between patients treated with lobectomy or thyroidectomy.
This lack of survival beneﬁt based on the type of procedure
performed was also apparent during subset analysis to
account for tumors ≥ 1cm[14]. The debate regarding the
extentofthyroidectomycontinues,butweandotherssuggest
that total thyroidectomy enables patients to be followed
for recurrence by testing blood thyroglobulin levels and
allows for the use of 131I screening and ablation. Although
a prospective randomized trial would provide guidance, it
will probably never be done because of the large number of
patients that would be required [15]. The poignant reality
unfortunately is that this issue will likely never be completely
resolved.
3. Prophylactic versusTherapeutic Central
Neck Dissection
Currently, the most widely debated subject in patients
with PTC is whether a prophylactic central neck dissection
(PCND) should be done in patients who are clinically
node negative by ultrasound, on physical exam, and by
intraoperative assessment. Prophylactic neck dissection is
deﬁnedastheremovalofseeminglynormallymphnodesand
ﬁbrofatty tissue during the initial operation. The rationale
to perform PCND is the questionable ability to adequately
evaluate the central neck compartment with preoperative
ultrasonography or with intraoperative assessment [16,
17]. However, others counter that intraoperative surgeon
assessment is an accurate predictor of who will beneﬁt from
PCNDandreportonlya3%localrecurrenceusingaselective
approach [16]. Occult lymph nodes are common (≥40%)
even in patients with small PTC (<1.5cm) [18]. However,
the vast majority of metastases involve only subclinical
(<2mm) microscopic metastases. A French study recently
reported that lymph node metastases are common even in
patients with small PTC (<2cm, T1) with no suspicious
lymphadenopathy on preoperative ultrasound. The authors’
reported that 45% of central and 47% of lateral lymph nodes
contain occult metastatic PTC when a PCND was performed
[19]. In other reports up to 60%–90% of PTC patients
have microscopic or macroscopic lymph node metastases at
presentation [20, 21].
The issue that remains to be addressed is whether the
presence of microscopic lymph node metastases has anyISRN Oncology 3
adverse eﬀect on clinical outcome. It has been suggested
that regional nodal metastases increase the risk of disease
recurrence but have minimal to no impact on survival
[16, 22]. Other reports document that patients with lymph
node metastases experience a higher morality than patients
without lymph node involvement [23]. This is also true in
patients over 45 years of age with PTC and lymph node
metastases [24]. Others, however, have shown no diﬀerence
in the recurrence rate or disease-speciﬁc mortality rate when
a total thyroidectomy was performed with or without a
PCND [25]. Nonetheless, other beneﬁts have been reported
when a PCND is performed. Some contest that PCND
provides more accurate staging, speciﬁcally in patients >
45 years of age [22, 26]. Another study demonstrated
that PCND resulted in lower postablation thyroglobulin
levels and more undetectable thyroglobulin levels than
those treated with thyroidectomy alone [27]. Similar to
other aforementioned studies, this study found no statistical
diﬀerence in the recurrence rate and mortality between the
two groups [27]. These opposing ﬁndings in retrospective
studies perpetuate the debate rather than provide a uniform
approachinthemanagementofPTC.Asigniﬁcantlimitation
is that studies in support of, or in opposition to, PCND are
retrospectiveandcannotaccuratelyaddressclinicaloutcome.
A prospective multicenter clinical trial has been submitted
to the National Institute of Health regarding the merits and
risks of an ipsilateral PCND.
Several reports have demonstrated that performing a
routine PCND during total thyroidectomy is associated with
a higher morbidity than thyroidectomy alone [28]. It has
been reported that permanent hypoparathyroidism results
in about 1%-2% of patients following a total thyroidectomy
but can occur in up to 14% of patients with a PCND
[29]. Mazzaferri et al. reviewed studies addressing the two
approaches and found that there was a higher risk of
temporary hypoparathyroidism with PCND compared to
thyroidectomy alone [17]. The authors also reported a
signiﬁcantly higher rate of hypoparathyroidism in patients
undergoing bilateral PCND compared to unilateral PCND,
with no diﬀerence in thyroglobulin levels, recurrence or
mortality [17]. Other authors’ have also corroborated these
ﬁndings [22]. On the other hand, there was conﬂicting
data for permanent hypoparathyroidism and transient and
permanent recurrent laryngeal nerve injury [17]. The higher
risk of complications with no diﬀerence in outcome in
patients treated with PTCN suggests a more temperate
approach. As such, the ATA guidelines consider a PCND in
patients with T3 and T4 tumors but not for smaller tumors
[1]. Others further recommend an approach based on




iodine (RAI) ablation is on par with the debate on the extent
of surgery required to adequately treat PTC patients. RAI
has routinely been utilized as an adjunct to surgical therapy
for patients with high-risk prognostic factors. The goal of
RAI therapy is to eradicate occult persistent or metastatic
disease to reduce the risk of recurrence and disease-speciﬁc
mortality. Given that PTC patients for the most part have
an excellent prognosis, the routine use of RAI has been
questioned [9]. The most recent ATA guidelines recommend
RAI in patients with gross extrathyroidal extension, known
distant metastases, and tumors > 4cm[1]. For patients who
do not meet these criteria and have tumors 1 to 4cm, a selec-
tive approach is recommended. RAI is not recommended
for tumors < 1cm, including multifocal micro-PTC, without
any high-risk features [1]. Some advocate no RAI ablation
for well-diﬀerentiated PTC between 1 and 4cm with less
than 3–5 metastatic cervical lymph nodes that are less than
5mmindiameter[31].Radioactiveiodineablationisusually
recommended for patients with more aggressive histological
variants of PTC and for those with primary tumors larger
than 2cm [31].
A recent study from the Memorial Sloan-Kettering
Cancer Center revisited the issue of RAI ablation [32]. This
retrospective study analyzed 289 patients of which 74% were
low-risk and 26% were intermediate-risk according to the
ATA risk stratiﬁcation. Patients were treated with total thy-
roidectomy (75%) or lobectomy (25%) and selective central
neck lymph node dissection (5%). Only 2% of those treated
with total thyroidectomy and 4% with lobectomy without
RAI recurred. When only tumors > 1cm were analyzed, the
recurrence rate following total thyroidectomy without RAI
remained low at 4%. The authors’ identiﬁed tumor size >
2cm, lymph node metastases, and ATA intermediate-risk
classiﬁcation as predictors of recurrence. The authors’ con-
clude that selected use of RAI aﬀords good clinical outcome
in appropriately selected patients [32]. Previous studies by
Mazzaferri and Jhiang [8], reported decreased recurrence in
patients treated with 131I ablation and with TSH suppression
therapy.
Based on current data, the beneﬁts of RAI ablation
to prevent persistent or recurrent disease and decrease
mortality is not completely clear. The current strategy of
selective use aﬀords the best management option and more
data regarding the management of such patients is needed.
5.MolecularMarkers
The controversy concerning the optimal treatment of
patients with PTC will continue, especially without data
from a randomized, prospective clinical trial. Therefore,
other factors will become an essential component in oper-
ative management. One of the most promising advances
in medicine is the application of personalized genomic
medicine. Our understanding of the genetic basis of PTC
is evolving and continues to improve. The identiﬁcation of
molecular markers in PTC should help appropriately risk-
stratify patients preoperatively by analysis of FNA biopsy
specimens and possibly allow for individualized operative
planning. The decision regarding the extent of thyroidec-
tomy and node dissection will, therefore, in the future
probably rely on preoperative molecular analysis of the
tumor.4 ISRN Oncology
Cellular signaling pathways have been established as
important factors in tumorigenesis. Activation of the
mitogen-activated protein kinase (MAPK)signaling pathway
is involved in the development of PTC. Several alterations
in the signaling pathway have been identiﬁed in PTC. One
of the most common mutations in PTC involves the BRAF
oncogene, occurring in approximately 40% of PTC [33].
BRAF is located on chromosome 7q24 and encodes a serine-
threonine kinase that mediates cellular response to growth
and diﬀerentiation signals. A point mutation in BRAF at
codon 600 leads to a valine to glutamate (V600E) alteration
and constitutive MAPK pathway stimulation [34]. Nearly
95% of BRAF mutations involve V600E [35]. Other signaling
alterations found in PTC include RET/PTC rearrangements
(20%–40%), neurotrophic receptor-tyrosine kinase 1 muta-
tions (5%–13%), and RAS proto-oncogene mutations [33].
Several studies have associated BRAF mutation with
poor prognostic factors. These include advanced age, male
gender, extrathyroidal extension, lymph node metastases,
and distant metastases [36–39]. BRAF mutation has also
been associated with advanced stage and higher risk of
recurrent and persistent disease [36, 38]. Other studies have
also demonstrated that the BRAF mutation was associated
with a lower survival [39]. The association between these
high-risk factors makes BRAF the most valuable prognostic
indicator to date. Although considerable information has
been reported regarding the inﬂuence of BRAF mutation as
a prognostic indictor of a worse outcome, no prospective
studies have been conducted evaluating its utility in long-
term clinical outcomes.
A recent study proposed a management algorithm
tailored to correspond with BRAF status [36]. The study
resulted in a 70% detection rate of BRAF on ﬁne-needle
aspiration in PTC patients and a positive predictive value
of 100%. BRAF positive PTC patients were also more likely
to have central lymph node metastases (47% versus 19%,
P = 0.003). The study showed that BRAF positive patients
were more likely to require cervical reoperations than BRAF
negative patients (10% versus 3%, P = 0.04) [36]. The
authors’furtherdemonstratedthatpreoperativeBRAFstatus
could have beneﬁcially altered the initial management in
24% of PTC. Based on the data, the authors’ proposed algo-
rithm entails routine ultrasound and lymph node mapping,
cytologic BRAF testing of suspicious thyroid nodules and
lymph nodes, and a total thyroidectomy for BRAF positive
tumors [36]. Although the results demonstrated that BRAF
positive patientsweremorelikelytohavecentrallymphnode
metastases, the authors stop short of recommending PCND
inBRAFpositivepatientsbutratherrecommendtheselective
approach as outlined in the ATA guidelines [1].
6. Conclusion
The debate surrounding the extent of initial thyroid surgery,
the beneﬁt of prophylactic neck dissection, and the need for
radioactive iodine ablation persists and is likely to endure.
The excellent prognosis of papillary thyroid cancer precludes
recruiting the extensive number of patients required to
conduct a meaningful prospective, randomized clinical trial
focused on addressing the controversies of appropriate
management. In its revised management guidelines, the
ATA attempts to provide management guidelines based on
risk stratiﬁcation. Although this serves as the best current
strategy, the divergence in expert opinion will continue to
perpetuatethedebate.Thecontroversiesregardingtheextent
of surgery and indications for RAI ablation will likely be
addressed by future scientiﬁc breakthroughs in molecular
prognostic markers that will help select individualized
management.
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